Cargando…
Repurposing the FDA‐approved anticancer agent ponatinib as a fluconazole potentiator by suppression of multidrug efflux and Pma1 expression in a broad spectrum of yeast species
Fungal infections have emerged as a major global threat to human health because of the increasing incidence and mortality rates every year. The emergence of drug resistance and limited arsenal of antifungal agents further aggravates the current situation resulting in a growing challenge in medical m...
Autores principales: | Liu, Lin, Jiang, Tong, Zhou, Jia, Mei, Yikun, Li, Jinyang, Tan, Jingcong, Wei, Luqi, Li, Jingquan, Peng, Yibing, Chen, Changbin, Liu, Ning‐Ning, Wang, Hui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8867973/ https://www.ncbi.nlm.nih.gov/pubmed/33955652 http://dx.doi.org/10.1111/1751-7915.13814 |
Ejemplares similares
-
FDA Approved Drug Library Screening Identifies Robenidine as a Repositionable Antifungal
por: Mei, Yikun, et al.
Publicado: (2020) -
Repurposing FDA-approved drugs for anti-aging therapies
por: Snell, Terry W., et al.
Publicado: (2016) -
Repurposing of FDA-approved drugs against cancer – focus on metastasis
por: Ozsvári, Béla, et al.
Publicado: (2016) -
Repurposing ferumoxytol: Diagnostic and therapeutic applications of an FDA-approved nanoparticle
por: Huang, Yue, et al.
Publicado: (2022) -
Can We Repurpose FDA-Approved Alefacept to Diminish the HIV Reservoir?
por: Zaidi, Asifa, et al.
Publicado: (2015)